LPL and hyperinsulinemic hypoglycemia, familial, 4: Alipogene tiparvovec (GlyberaR) [14], the first gene therapy for patients with familial LPL deficiency, was withdrawn from the market due to its extremely high cost and insufficient TG-lowering effect.